Education
About Us
Working with TipRanks
Follow Us
Abivax SA Sponsored ADR (ABVX)
NASDAQ:ABVX
ABVX Stock Chart & Stats
$121.28
-$0.09(-1.29%)
At close: 4:00 PM EST
$121.28
-$0.09(-1.29%)
Day’s Range― - ―
52-Week Range$4.77 - $148.83
Previous CloseN/A
Volume62.24K
Average Volume (3M)807.39K
Market Cap
$9.57B
Enterprise Value$8.15B
Total Cash (Recent Filing)$60.95M
Total Debt (Recent Filing)$84.57M
Price to Earnings (P/E)―
Beta2.48
Next Earnings
Mar 23, 2026EPS Estimate
-1.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.47
Shares Outstanding79,072,624
10 Day Avg. Volume821,553
30 Day Avg. Volume807,392
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)10.98
Price to Sales (P/S)41.30
P/FCF Ratio-2.88
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue865.61
Enterprise Value/Gross Profit865.61
Enterprise Value/Ebitda-36.13
Forecast
1Y Price Target
$148.50Price Target Upside22.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.48
Revenue Forecast (FY)$5.26M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyInduction and maintenance results showing rapid onset of effect and consistent benefit versus placebo across different patient types increase the likelihood of meaningful clinical efficacy and broader treatment adoption.
Commercial Potential And ValuationAnalyst valuation upgrades and market surveys indicating strong uptake, particularly in second‑line use, point to substantial commercial upside beyond current ulcerative colitis assumptions.
Therapeutic DifferentiationPreclinical evidence of an anti‑fibrotic effect combined with once‑daily oral dosing could uniquely position the medicine in Crohn's disease and support uptake across multiple treatment lines.
Bears Say
Funding RiskHigh cash burn relative to available resources increases the likelihood of additional fundraising that may dilute shareholders and disrupt development timelines.
Reproductive RiskAggressive contraception requirements and possible teratogenic effects could restrict use in women of childbearing potential and complicate real-world prescribing.
Safety SignalsPancreatic enzyme elevations in trials and potential links between elevated miR-124 and cardiac dysfunction raise concerns about serious safety risks that could limit labeling or physician uptake.
Abivax SA Sponsored ADR News
ABVX FAQ
What was Abivax SA Sponsored ADR’s price range in the past 12 months?
Abivax SA Sponsored ADR lowest stock price was $4.77 and its highest was $148.83 in the past 12 months.
What is Abivax SA Sponsored ADR’s market cap?
Abivax SA Sponsored ADR’s market cap is $9.57B.
When is Abivax SA Sponsored ADR’s upcoming earnings report date?
Abivax SA Sponsored ADR’s upcoming earnings report date is Mar 23, 2026 which is in 21 days.
How were Abivax SA Sponsored ADR’s earnings last quarter?
Abivax SA Sponsored ADR released its earnings results on Dec 15, 2025. The company reported -$2.472 earnings per share for the quarter, missing the consensus estimate of -$0.786 by -$1.686.
Is Abivax SA Sponsored ADR overvalued?
According to Wall Street analysts Abivax SA Sponsored ADR’s price is currently Undervalued.
Does Abivax SA Sponsored ADR pay dividends?
Abivax SA Sponsored ADR does not currently pay dividends.
What is Abivax SA Sponsored ADR’s EPS estimate?
Abivax SA Sponsored ADR’s EPS estimate is -1.46.
How many shares outstanding does Abivax SA Sponsored ADR have?
Abivax SA Sponsored ADR has 79,072,624 shares outstanding.
What happened to Abivax SA Sponsored ADR’s price movement after its last earnings report?
Abivax SA Sponsored ADR reported an EPS of -$2.472 in its last earnings report, missing expectations of -$0.786. Following the earnings report the stock price went down -5.877%.
Which hedge fund is a major shareholder of Abivax SA Sponsored ADR?
Currently, no hedge funds are holding shares in ABVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abivax SA Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$148.50 (22.44% Upside)
$148.50 (22.44% Upside)
Blogger Sentiment
Bullish
ABVX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
Abivax SA Sponsored ADR
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
ABVX Stock 12 Month Forecast
Average Price Target
$148.50
▲(22.44% Upside)
Technical Analysis
Cytokinetics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Avidity Biosciences
―
Nuvalent
―
Ownership Overview
―
Insiders
5.05% Mutual Funds
8.26% Other Institutional Investors
82.99% Public Companies and Individual Investors